Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 872

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

Open access
Randall, Marcus E., Filiaci, Virginia L., Muss, Hyman, Spirtos, Nick M., Mannel, Robert S., Fowler, Jeffrey, Thigpen, J. Tate, Benda, Jo Ann·2006·Journal of Clinical Oncology
DOI 10.1200/jco.2004.00.7617
Open this paper in CoChat — free account

Abstract

Purpose: To compare whole-abdominal irradiation (WAI) and doxorubicin-cisplatin (AP) chemotherapy in women with stage III or IV endometrial carcinoma having a maximum of 2 cm of postoperative residual disease. Patients and Methods: Four hundred twenty-two patients were entered onto this trial. Of 396 assessable patients, 202 were randomly allocated to receive WAI, and 194 were allocated to receive AP. Irradiation dosage was 30 Gy in 20 fractions, with a 15-Gy boost. Chemotherapy consisted of doxorubicin 60 mg/m 2 and cisplatin 50 mg/m 2 every 3 weeks for seven cycles, followed by one cycle of cisplatin. Results: Most patient and tumor characteristics were well balanced. The median patient age was 63 years; 50% had endometrioid tumors. Median follow-up time was 74 months. The hazard ratio for progression adjusted for stage was 0.71 favoring AP (95% CI, 0.55 to 0.91; P < .01). At 60 months, 50% of patients receiving AP were predicted to be alive and disease free when adjusting for stage compared with 38% of patients receiving WAI. The stage-adjusted death hazard ratio was 0.68 (95% CI, 0.52 to 0.89; P < .01) favoring AP. Moreover, at 60 months and adjusting for stage, 55% of AP patients were predicted to be alive compared with 42% of WAI patients. Greater acute toxicity was seen with AP. Treatment probably contributed to the deaths of eight patients (4%) on the AP arm and five patients (2%) on the WAI arm. Conclusion: Chemotherapy with AP significantly improved progression-free and overall survival compared with WAI. Nevertheless, further advances in efficacy and reduction in toxicity are clearly needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.00.7617

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 29

  1. 10.1006/gyno.1999.5569 · doi:10.1006/gyno.1999.5569
  2. 10.1016/0360-3016(91)90744-O · doi:10.1016/0360-3016(91)90744-o
  3. 10.1002/1097-0142(19930515)71:10<3076::AID-CNCR2820711030>3.0.CO;2-Z · doi:10.1002/1097-0142(19930515)71:10<3076::aid-cncr2820711030>3.0.co;2-z
  4. 10.1016/0360-3016(89)90948-6 · doi:10.1016/0360-3016(89)90948-6
  5. 10.1006/gyno.2000.5746 · doi:10.1006/gyno.2000.5746
  6. 10.1200/JCO.1994.12.7.1408 · doi:10.1200/jco.1994.12.7.1408
  7. 10.1006/gyno.1999.5444 · doi:10.1006/gyno.1999.5444
  8. 10.1006/gyno.2000.5827 · doi:10.1006/gyno.2000.5827
  9. 10.1046/j.1525-1438.1998.09892.x · doi:10.1046/j.1525-1438.1998.09892.x
  10. 10.1006/gyno.1996.0326 · doi:10.1006/gyno.1996.0326
  11. 10.1046/j.1525-1438.1998.09857.x · doi:10.1046/j.1525-1438.1998.09857.x
  12. 10.1016/S0360-3016(97)00581-6 · doi:10.1016/s0360-3016(97)00581-6
  13. 10.1002/(SICI)1097-0142(19960315)77:6<1115::AID-CNCR17>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19960315)77:6<1115::aid-cncr17>3.0.co;2-4
  14. 10.1006/gyno.2002.6713 · doi:10.1006/gyno.2002.6713
  15. 10.1046/j.1525-1438.1999.99028.x · doi:10.1046/j.1525-1438.1999.99028.x
  16. 10.1006/gyno.2001.6278 · doi:10.1006/gyno.2001.6278
  17. 10.1016/0360-3016(89)90367-2 · doi:10.1016/0360-3016(89)90367-2
  18. 10.1006/gyno.2001.6189 · doi:10.1006/gyno.2001.6189
  19. 10.1002/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO;2-U · doi:10.1002/1097-0142(19930601)71:11<3697::aid-cncr2820711137>3.0.co;2-u
  20. 10.1016/0090-8258(87)90229-0 · doi:10.1016/0090-8258(87)90229-0
  21. 10.1002/(SICI)1520-6823(1996)4:3<122::AID-ROI4>3.0.CO;2-# · doi:10.1002/(sici)1520-6823(1996)4:3<122::aid-roi4>3.0.co;2-#
  22. 10.1016/0360-3016(93)90276-2 · doi:10.1016/0360-3016(93)90276-2
  23. 10.1006/gyno.1997.4796 · doi:10.1006/gyno.1997.4796
  24. 10.1006/gyno.2001.6157 · doi:10.1006/gyno.2001.6157
  25. Corn BW, Lanciano RM, Greven KM, et al: Endometrial cancer with para-aortic adenopathy: Patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 24:223,1992-227, · doi:10.1016/0360-3016(92)90675-8
  26. 10.1016/0090-8258(87)90236-8 · doi:10.1016/0090-8258(87)90236-8
  27. 10.1016/0002-9378(86)90815-X · doi:10.1016/0002-9378(86)90815-x
  28. Rose PG, Cha SD, Tak WK, et al: Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 24:229,1992-233, · doi:10.1016/0360-3016(92)90676-9
  29. 10.1038/bjc.1997.313 · doi:10.1038/bjc.1997.313

Cited by

See all 872

Metadata

Authors
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A.
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2006-01-01
Volume
24
Issue
1
Pages
36-44
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2004.00.7617
OpenAlex
W2098960933
Cited by
872
References
20
FWCI
37.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. https://app.cochat.ai/papers/10.1200/jco.2004.00.7617
The paper
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006). Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.00.7617

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.